{"nctId":"NCT00080301","briefTitle":"Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","startDateStruct":{"date":"2003-09"},"conditions":["Breast Cancer","Metastases"],"count":752,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Ixabepilone + Capecitabine"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Capecitabine"]}],"interventions":[{"name":"Ixabepilone + Capecitabine","otherNames":["BMS-247550","IXEMPRA","Epothilone"]},{"name":"Capecitabine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.\n* Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).\n* Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.\n* Patients must be resistant to taxane therapy.\n* Patients may not have any history of brain and/or leptomeningeal metastases.\n* Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).\n* Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)","description":"PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","spread":null},{"groupId":"OG001","value":"4.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) Per IRRC","description":"Participants with best response of \"Complete\" or \"Partial\" according to Response Evaluation Criteria in Solid Tumors (RECIST) a 4-item scale wherein complete response=disappearance of all target lesions and partial response=30% decrease in the sum of the longest diameter of target lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response Per IRRC","description":"Computed for all patients with a best response of \"Partial\" or \"Complete\" per RECIST (a 4-item scale as described in previous outcome measure), calculated from the time when these criteria were first met until the first date of documented progression or death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response Per IRRC","description":"Time to response was summarized using descriptive statistics and was defined as the time from first dose of study treatment until measurement criteria were first met for Partial Response or Complete Response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death. Participants who did not die at the time of the analysis were censored at the latest follow-up date. Median OS with 95% CI was estimated using the Kaplan Meier product limit method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-related Safety Summary","description":"Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)","description":"Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":127,"n":368},"commonTop":["PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME","NAUSEA","DIARRHOEA","VOMITING","FATIGUE"]}}}